This is a must-watch. Thanks Eire.
* Excellent anecdotally observed results from SAVR, especially in valve area, which is essentially the same as a healthy natural heart valve.
* TAVR study progressing on track.
* Bench-test valve has passed 500M, roughly equating to more than a decade of use in humans, with no deterioration.
* New 3D ADAPT product for heart by-passes, currently being tested. No real alternative available in a huge market.
* Several completed tests (already disclosed) showing ADAPT tissue strongly superior to competitors in its non-calcification properties.
* Current calcification study to report later this year.
* Market is competitive, with two major players, but liable to turn quickly in favour of a clinically superior product.
* No obvious competitive disruptive technology on the horizon.
* Strong news-flow for the next 18 months to 2 years.
IMHO, the competitive advantage of the ADAPT intellectual property is the gunpowder in this stock.
DYOR and listen to the interview.
Interview with CEO Wayne Paterson re: 2020 milestones, page-2
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.30 |
Change
0.300(1.67%) |
Mkt cap ! $351.7M | |||
| Open | High | Low | Value | Volume |
| $18.25 | $18.30 | $18.01 | $12.33K | 679 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $18.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.30 | 247 | 2 |
View Market Depth
| Last trade - 14.56pm 04/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |